Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.
A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.
The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.
A prospective study has revealed that greater fasting glucose variability during young adulthood is independently associated with increased risk for coronary artery calcification progression in middle age.
Dapagliflozin reduces the risk for cardiovascular events in people with type 2 diabetes, including those with peripheral artery disease, without increasing the risk for adverse limb events, show DECLARE-TIMI 58 data.
Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.
Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.
Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.
The addition of rivaroxaban to aspirin results in a similar relative reduction in the risk for cardiovascular events among patients with stable atherosclerosis and a history of atherosclerotic disease regardless of whether or not they have diabetes, suggests a subgroup analysis of the COMPASS trial.
Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.
More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.
An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.
Children born to mothers with diabetes have a higher risk for early-onset, non-congenital cardiovascular disease in childhood and early adulthood than those born to mothers without diabetes, suggest findings from a large observational study.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.